Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene

被引:14
作者
Douchi, T [1 ]
Oki, T [1 ]
Yamasaki, H [1 ]
Nakae, M [1 ]
Imabayashi, A [1 ]
Nagata, Y [1 ]
机构
[1] Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima 8908520, Japan
关键词
clomiphene responders; clomiphene nonresponders; body fat distribution; polycystic ovary syndrome;
D O I
10.1111/j.0001-6349.2004.00369.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. To investigate the difference in the response to clomiphene citrate (CC) based on body fat distribution in women with polycystic ovary syndrome (PCOS). Methods. Ninety anovulatory PCOS women were divided into two subgroups based on treatment response: women who ovulated with CC (CC responders, n = 49) and those who did not ovulate with CC (CC nonresponders, n = 41). Baseline characteristics included age, age at menarche, height, weight and body mass index [BMI; weight/(height)(2)]. Percentage of body fat, body fat mass and the ratio of trunk fat to leg fat mass amount (trunk-leg fat ratio) were measured by dual-energy X-ray absorptiometry (DEXA). Results. Age, age at menarche and height did not differ between the two groups. However, trunk-leg fat ratio in CC responders (0.9 +/- 0.4) was significantly lower than that in CC nonresponders (1.3 +/- 0.4) (p < 0.001). Percentage of body fat, body fat mass and BMI were also lower in CC responders (p < 0.01). On multiple regression analysis, however, trunk-leg fat ratio proved to be a superior predictor of CC responder to percentage of body fat, BMI or body fat mass (standardized regression coefficient greater than or equal to 0.510; t-values greater than or equal to 3.432; p < 0.001). Conclusions. Response to CC in anovulatory PCOS women differs with body fat distribution.
引用
收藏
页码:838 / 841
页数:4
相关论文
共 15 条
[1]   The android woman - A risky condition [J].
Bjorntorp, P .
JOURNAL OF INTERNAL MEDICINE, 1996, 239 (02) :105-110
[2]  
DAHLGREN E, 1992, FERTIL STERIL, V57, P505
[3]   BODY-FAT DISTRIBUTION IN WOMEN WITH POLYCYSTIC-OVARY-SYNDROME [J].
DOUCHI, T ;
IJUIN, H ;
NAKAMURA, S ;
OKI, T ;
YAMAMOTO, S ;
NAGATA, Y .
OBSTETRICS AND GYNECOLOGY, 1995, 86 (04) :516-519
[4]   Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome [J].
Ehrmann, DA ;
Cavaghan, MK ;
Imperial, J ;
Sturis, J ;
Rosenfield, RL ;
Polonsky, KS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :524-530
[5]   RELATION OF BODY-FAT DISTRIBUTION TO METABOLIC COMPLICATIONS OF OBESITY [J].
KISSEBAH, AH ;
VYDELINGUM, N ;
MURRAY, R ;
EVANS, DJ ;
HARTZ, AJ ;
KALKHOFF, RK ;
ADAMS, PW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (02) :254-260
[6]   Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome [J].
Kolodziejczyk, B ;
Duleba, AJ ;
Spaczynski, RZ ;
Pawelczyk, L .
FERTILITY AND STERILITY, 2000, 73 (06) :1149-1154
[7]  
LOBO RA, 1982, FERTIL STERIL, V37, P168
[8]   High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome [J].
Mitwally, MFM ;
Kuscu, NK ;
Yalcinkaya, TM .
HUMAN REPRODUCTION, 1999, 14 (11) :2700-2703
[9]  
Murakawa H, 1999, J REPROD MED, V44, P23
[10]   Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome [J].
Nestler, JE ;
Jakubowicz, DJ ;
Evans, WS ;
Pasquali, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (26) :1876-1880